Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Lutetium
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Radioisotopes

abstract

  • The MTD of (177)Lu-J591 is 70 mCi/m(2). Multiple doses of 30 mCi/m(2) are well tolerated. Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.05.160

PubMed ID

  • 15837970

Additional Document Info

start page

  • 4591

end page

  • 601

volume

  • 23

number

  • 21